ENTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. Enanta Pharmaceuticals's Net Income for the three months ended in Sep. 2024 was $-28.82 Mil. Enanta Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was $14.61 Mil. Therefore, Enanta Pharmaceuticals's net margin for the quarter that ended in Sep. 2024 was -197.32%.
The historical rank and industry rank for Enanta Pharmaceuticals's Net Margin % or its related term are showing as below:
The historical data trend for Enanta Pharmaceuticals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enanta Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Sep15 | Sep16 | Sep17 | Sep18 | Sep19 | Sep20 | Sep21 | Sep22 | Sep23 | Sep24 | |||||||||||
Net Margin % | Get a 7-Day Free Trial | -29.53 | -81.38 | -141.31 | -168.95 | -171.58 |
Enanta Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Net Margin % | Get a 7-Day Free Trial | -148.46 | -185.56 | -182.70 | -126.08 | -197.32 |
For the Biotechnology subindustry, Enanta Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Enanta Pharmaceuticals's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Enanta Pharmaceuticals's Net Margin for the fiscal year that ended in Sep. 2024 is calculated as
Net Margin | = | Net Income (A: Sep. 2024 ) | / | Revenue (A: Sep. 2024 ) |
= | -116.045 | / | 67.635 | |
= | -171.58 % |
Enanta Pharmaceuticals's Net Margin for the quarter that ended in Sep. 2024 is calculated as
Net Margin | = | Net Income (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | -28.823 | / | 14.607 | |
= | -197.32 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enanta Pharmaceuticals (NAS:ENTA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott T. Rottinghaus | officer: Chief Medical Officer | C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472 |
Tara Lynn Kieffer | officer: Sr. VP, New Product Dev. | C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472 |
Terry Vance | director | C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472 |
Brendan Luu | officer: Sr. VP, Business Dev. | C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472 |
Yat Sun Or | officer: Chief Scientific Officer | C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472 |
Jay R. Luly | director, officer: President and CEO | C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472 |
Nathaniel S. Gardiner | director | C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472 |
Paul J Mellett | officer: Treasurer and CFO | C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472 |
Nathalie Adda | officer: Sr. VP & Chief Medical Officer | C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472 |
Carter Bruce L A | director | C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102 |
Lesley Russell | director | 41 MOORES RD., FRAZER PA 19355 |
Yujiro S Hata | director | C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016 |
Mark G Foletta | director | AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121 |
Kristine Peterson | director | AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355 |
George Golumbeski | director | C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901 |
From GuruFocus
By Business Wire • 05-29-2024
By Business Wire • 05-07-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 05-06-2024
By GuruFocus Research • 02-06-2024
By Business Wire • 08-05-2024
By GuruFocus Research • 05-07-2024
By Business Wire • 04-30-2024
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.